Survival and Mortality in Hospitalized Children with COVID-19: A Referral Center Experience in Yazd, Iran
Table 3
Descriptive statistics of drugs being used for children with COVID-19 in Shahid Sadoughi Hospital in Yazd.
Variables
Total (n = 183)
Survived (n = 159)
Deceased (n = 24)
Cramer’s V/Eta
value
Kaletra
Yes
29.0 (15.8)
25.0 (15.7)
4.0 (16.7)
0.009
0.9
No
154.0 (84.2)
134.0 (84.3)
20.0 (83.3)
Hydroxychloroquine
Yes
23.0 (12.6)
19.0 (12.0)
4.0 (16.7)
0.05
0.52
No
160.0 (87.4)
140.0 (88.0)
20.0 (83.3)
Oseltamivir
Yes
11.0 (6.0)
8.0 (5.0)
3.0 (12.5)
0.10
0.15
No
172.0 (94.0)
151.0 (95.0)
21.0 (87.5)
Enoxaparin
Yes
27.0 (15.0)
24.0 (15.0)
3.0 (12.5)
0.025
0.74
No
156.0 (85.0)
135.0 (85.0)
21.0 (87.5)
Ribavirin tab
Yes
2.0 (1.0)
2.0 (1.3)
0.0 (0.0)
0.04
0.58
No
181.0 (99.0)
157.0 (98.7)
24.0 (100)
ASA
Yes
13.0 (7.0)
13.0 (8.0)
0.0 (0.0)
0.1
0.15
No
170.0 (93.0)
146.0 (92.0)
24.0 (100)
Remdesivir
Yes
53.0 (29.0)
45.0 (28.0)
8.0 (33.0)
0.04
0.61
No
130.0 (71.0)
114.0 (72.0)
16.0 (67.0)
Dexamethasone amp
Yes
34.0 (18.5)
29.0 (18.0)
5.0 (21.0)
0.02
0.76
No
149.0 (81.5)
130.0 (82.0)
19.0 (79.0)
Dexamethasone tab
Yes
2.0 (1.0)
2.0 (1.3)
0.0 (0.0)
0.04
0.58
No
181.0 (99.0)
157.0 (98.7)
24.0 (100)
Heparin
Yes
14.0 (8.0)
13.0 (8.0)
1.0 (4.0)
0.05
0.49
No
169.0 (92.0)
146.0 (92.0)
23.0 (96.0)
Interferon
Yes
14.0 (8.0)
12.0 (7.5)
2.0 (8.5)
0.01
0.89
No
169.0 (92.0)
147.0 (92.5)
22.0 (91.5)
Favipiravir
Yes
19.0 (10.5)
19.0 (12.0)
0.0 (0.0)
0.13
0.07
No
164.0 (89.5)
140.0 (88.0)
24.0 (100)
Vitamin D
Yes
17.0 (9.5)
16.0 (10.0)
1.0 (4.0)
0.07
0.35
No
166.0 (90.5)
143.0 (90.0)
23.0 (96.0)
Famotidine
Yes
27.0 (15.0)
26.0 (16.5)
1.0 (4.0)
0.12
0.18
No
156.0 (85.0)
133.0 (83.5)
23.0 (96.0)
Methylprednisolone
Yes
28.0 (15.0)
21.0 (13.0)
7.0 (29.0)
0.15
0.04
No
155.0 (85.0)
138.0 (87.0)
17.0 (71.0)
Intravenous immunoglobulin
Yes
6.0 (3.5)
5.0 (3.0)
1.0 (4.0)
0.02
0.79
No
177.0 (96.5)
154.0 (97.0)
23.0 (96.0)
Frequency (%) was used for describing the drugs being used. The Cramer’s V, chi-square, and Fisher exact tests were used to measure the association between the drugs being used and status.
